Related Experiment Video
Updated: May 24, 2026
Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
Treatment outcomes of Hodgkin lymphoma in the Czech Republic
Insights
Treatment for Hodgkin
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Hodgkin's lymphoma (HL) is a significant hematologic malignancy.
- Treatment efficacy and patient prognosis are critical areas of research.
- The Czech HL Registry provides valuable data for retrospective analysis.
Purpose of the Study:
- To evaluate the effectiveness of various treatment protocols for Hodgkin's lymphoma.
- To analyze the impact of treatment on patient survival outcomes.
- To assess prognosis based on patient age and disease stage.
Main Methods:
- Retrospective analysis of 2,241 classical HL (cHL) and 130 NLPHL patients.
- Data collected from the Czech HL Registry between 2000 and 2024.
- Evaluation of treatment regimens including ABVD, BEACOPP, and radiotherapy (RT), with or without rituximab.
Main Results:
- For cHL patients under 60, 10-year progression-free survival (PFS) ranged from 83.9% to 91.5%, and overall survival (OS) from 92.6% to 96.6%.
- For cHL patients aged 60 and above, 10-year PFS ranged from 36.4% to 67.0%, and OS from 45.7% to 74.2%.
- 10-year PFS and OS for NLPHL patients were 77.5% and 95.8%, respectively.
Conclusions:
- Younger HL patients (<60 years) demonstrate excellent prognosis with over 90% 10-year OS.
- Older HL patients (≥60 years) have a median OS of 10 years.
- Future treatments incorporating checkpoint inhibitors or brentuximab vedotin are expected to enhance efficacy and reduce toxicity.
Background:
The aim of this analysis was to assess the efficacy of treatment and its impact on prognosis of patients with Hodgkin's lymphoma (HL) enrolled in the Czech HL Registry.
Patients And Methods:
Overall 2,241 patients with classical HL (cHL) and 130 patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) treated between 2000 and 2024 were analyzed. Median age at diagnosis was 37 years in cHL and 42 years in NLPHL.
Results:
The most common chemotherapy regimen in early and intermediate stages was ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) in combination with radiotherapy (RT). Moreover, two cycles of escalated BEACOPP (bleomycin, etoposide doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) combined with two cycles of ABVD and RT were used in patients aged < 60 years in intermediate stages. The most common therapy in advanced stages was escalated BEACOPP (4-8 cycles) in patients aged < 60 years and ABVD (6-8 cycles) in patients aged ≥ 60 years. Patients with NLPHL were treated with RT alone or with combination of rituximab and chemotherapy or with a combination of RT based on clinical stages. The 10-year progression-free survival (PFS) and overall survival (OS) in patients with cHL aged < 60 years were: in early stages 91.5% and 94.2%, in intermediate stages 91.0% and 96.6% and in advanced stages 83.9% and 92.6%, respectively. The 10-year PFS and OS in cHL ≥ 60 years were: in early stages 67.0% and 74.2%, in intermediate stages 36.4% and 45.7%, in advanced stages 41.6% and 52.0%, respectively. The 10-year PFS and OS in NLPHL patients were 77.5% and 95.8%.
Conclusion:
Based on the data from the Czech HL Registry, the prognosis of HL patients aged < 60 years is excellent: the 10-year OS is achieved in more than 90% of cases. Median OS of patients aged ≥ 60 years is 10 years. Implementation of checkpoint inhibitors or brentuximab vedotin into the first-line treatment will further improve its efficacy and reduce the toxicity.
Related Concept Videos
02:56Treatment Resistant Cancers
01:21Cancer Survival Analysis
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...